Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Neuropharmacology. 2019 Feb 20;149:161–168. doi: 10.1016/j.neuropharm.2019.02.024

Figure 5: Neuronal p38 MAPK activation is required for gp120-induced increases in tonic inhibition.

Figure 5:

(A) The p38 antagonist SB203,580 (10 µM) inhibits gp120-induced increases in bicuculline-sensitive current normalized to whole-cell capacitance (two-way ANOVA; F (1,21)=9.14, p=0.006). (B) SB202,474 (10 µM), an inactive analog of SB203580, does not affect the gp120-induced increase in bicuculline-sensitive current (two-way ANOVA; F(1,17)=1.09, p=0.3). (C) RapRp38 expression prevents the gp120-induced increase in tonic inhibition (two-way ANOVA; F(1,27)=5.02, p=0.03). (D) Treatment with rapamycin (200 nM) increases tonic inhibition in RapRp38 expressing cells significantly more than cells expressing tdTomato alone (two-way ANOVA; F(1,22)=6.08, p=0.02). (E) Cycloheximide (CHX) (10 µM) does not affect the gp120-induced increase in tonic inhibition (two-way ANOVA, F(1,24)=0.003, p=0.9). Data are expressed as individual data points with mean ± SEM. Two-way ANOVAs were followed by Tukey’s post hoc test, *p<0.05, **p<0.01, ***p<.001 compared to untreated control. # p<0.05, ##p<0.01, compared to gp120 (A,C) or rapamycin (D) alone (untreated or TdTomato).